Lightstone Ventures is a global venture capital firm that invests in personalized medicines and targeted therapeutics.
Key people at Lightstone Ventures.
Lightstone Ventures is a global venture capital firm founded in 2012 with a mission to empower visionary entrepreneurs developing innovative therapeutics and medical technologies that address unmet patient needs. The firm specializes in early-stage investments across biotech, medtech, and digital health, with a particular focus on personalized medicines and targeted therapeutics. Lightstone’s investment philosophy centers on patient capital, strategic guidance, and long-term partnership—supporting companies from inception through commercialization. Its portfolio spans groundbreaking startups in oncology, immunology, CNS disorders, and rare diseases, making a significant impact on the life sciences startup ecosystem by accelerating the translation of scientific breakthroughs into real-world therapies.
Lightstone Ventures was established in 2012 by a team of seasoned investors and industry veterans, including Managing Partner Mike Carusi and Partner Jean George, both of whom bring decades of experience in life sciences venture capital. The firm was born out of a recognition that transformative medical innovation often requires not just capital, but deep operational expertise and strategic mentorship. Over the years, Lightstone has evolved from a U.S.-focused fund to a global player, opening offices in Boston, Portola Valley (California), and Dublin, Ireland. This expansion has allowed the firm to tap into international talent, scientific breakthroughs, and funding networks, positioning it at the forefront of the global biotech and medtech investment landscape.
Lightstone Ventures is riding the wave of a rapidly evolving biotech and medtech landscape, where advances in genomics, artificial intelligence, and targeted drug delivery are enabling a new era of personalized medicine. The timing is critical, as the demand for precision therapies—especially in oncology, autoimmune diseases, and rare disorders—has never been greater. Market forces such as increased regulatory support for innovation, growing patient advocacy, and the rise of data-driven drug discovery are working in Lightstone’s favor. By backing companies that leverage these trends, Lightstone is not only shaping the future of healthcare but also influencing how venture capital is deployed in the life sciences sector, setting a benchmark for strategic, impact-driven investing.
Looking ahead, Lightstone Ventures is poised to deepen its impact as the convergence of biotechnology, AI, and digital health accelerates. The firm’s global footprint and focus on personalized medicine position it to capture emerging opportunities in gene therapies, cell therapies, and AI-driven drug discovery. As the healthcare ecosystem continues to prioritize patient-centric innovation, Lightstone’s ability to nurture and scale breakthrough companies will be more critical than ever. The future of medicine is increasingly personalized, and Lightstone Ventures is at the heart of this transformation—empowering the next generation of founders to bring targeted, life-changing therapies to patients around the world.
Key people at Lightstone Ventures.
